Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas

Launched by FUDAN UNIVERSITY · Mar 31, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called Tamoxifen for patients with a specific type of pancreatic tumor known as Solid Pseudopapillary Tumor of the Pancreas (SPTP). The goal is to see if Tamoxifen can help treat this advanced form of the disease, especially for patients whose tumors cannot be surgically removed or who have had their tumors return after previous treatments. The trial is currently looking for participants aged 14 to 80 who have been diagnosed with advanced SPTP and have tumors that express certain hormone receptors.

To join the study, participants need to have at least one measurable tumor and a good level of overall health, as determined by a performance status scale. They should also be able to take medication by mouth and attend regular study visits. However, there are some exclusions, such as having other types of tumors, severe health issues, or being pregnant. If eligible, participants will receive Tamoxifen and be monitored closely to see how well it works for their condition. This trial provides an opportunity for patients to contribute to research that may improve treatment options for this rare type of pancreatic cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 14-80 years.
• • 2. Histologically confirmed advanced SPTP with ER/PR+.
• 3. Advanced disease:
• • Unresectable primary tumor or distant metastasis (liver, lung, peritoneum, etc.).
• • Recurrent or refractory after prior surgery/systemic therapy.
• • 4. ≥1 measurable lesion.
• • 5. ECOG performance status 0-2.
• • 6. Life expectancy ≥1 month.
• • 7. Able to comply with study visits and oral medication.
• Exclusion Criteria:
• • 1. Non-SPTP pathology.
• • 2. Active gastrointestinal inflammation/infection (e.g., pancreatitis).
• • 3. Pregnancy/lactation.
• • 4. Severe organ dysfunction (renal, cardiac, hepatic, or pulmonary).
• • 5. Uncontrolled comorbidities (e.g., CNS disorders, unstable angina).
• • 6. Conditions compromising patient safety or data integrity.